Lubner David Charles
SEC-identified person · CIK 1572000 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Dyne Therapeutics, Inc. DYN | Director | filed 2020–2026 |
| Glycomimetics INC GLYC | Director | filed 2025–2026 |
| Arcellx, Inc. ACLX | Director | filed 2022–2026 |
| Cargo Therapeutics, Inc. CRGX | Director | filed 2023–2025 |
| Vor Biopharma Inc. VOR | Director | filed 2021–2025 |
| Therapeutics Acquisition Corp. TXAC | Director | filed 2020–2023 |
| Gemini Therapeutics, Inc. /DE IRON | Director | filed 2021–2022 |
| Ra Pharmaceuticals, Inc. RARX | VP Operations & CFO | filed 2016–2020 |
| Nightstar Therapeutics plc NITE | Director | filed 2019–2019 |
| Tetraphase Pharmaceuticals INC TTPH | SVP and CFO | filed 2013–2015 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.